优化结直肠癌的免疫治疗。
Optimizing immunotherapy for colorectal cancer.
机构信息
Molecular Pharmacology Program, Sloan Kettering Institute and Gastrointestinal Oncology Service, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Nat Rev Gastroenterol Hepatol. 2022 Feb;19(2):93-94. doi: 10.1038/s41575-021-00569-4.
Abstract
Important colorectal cancer (CRC) studies in 2021, including a new standard of care for first-line treatment of MSI-H–dMMR metastatic CRC, single-cell and spatial analysis of primary tumours and investigations of diet in preclinical models of cancer initiation, have provided novel insights into the CRC immune microenvironment.
摘要
2021 年重要的结直肠癌（CRC）研究，包括微卫星高度不稳定（MSI-H）-错配修复缺陷（dMMR）转移性 CRC 一线治疗的新标准，原发性肿瘤的单细胞和空间分析，以及癌症起始的临床前模型中饮食的研究，为 CRC 免疫微环境提供了新的见解。
相似文献
1
Optimizing immunotherapy for colorectal cancer.优化结直肠癌的免疫治疗。
Nat Rev Gastroenterol Hepatol. 2022 Feb;19(2):93-94. doi: 10.1038/s41575-021-00569-4.
2
Evaluating Immunotherapy in Nonmetastatic Colorectal Cancer.评估非转移性结直肠癌中的免疫疗法。
Oncology (Williston Park). 2019 May 14;33(5):178-80.
3
Immunotherapy in colorectal cancer with mismatch repair deficiency.错配修复缺陷型结直肠癌的免疫治疗
Clin Adv Hematol Oncol. 2019 May;17(5):265-267.
4
Labetuzumab govitecan in metastatic colorectal cancer.戈沙妥珠单抗治疗转移性结直肠癌
Lancet Oncol. 2017 Oct;18(10):e563. doi: 10.1016/S1470-2045(17)30664-2. Epub 2017 Aug 24.
5
The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.肿瘤微环境与结直肠癌治疗策略的作用。
Front Immunol. 2021 Dec 2;12:792691. doi: 10.3389/fimmu.2021.792691. eCollection 2021.
6
The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.结直肠癌转移的肿瘤微环境：癌症免疫治疗的新机遇。
Immunotherapy. 2020 Oct;12(14):1083-1100. doi: 10.2217/imt-2020-0026. Epub 2020 Aug 13.
7
HER2 and immunotherapy using monoclonal antibodies in colorectal cancer.人表皮生长因子受体2（HER2）与结直肠癌单克隆抗体免疫疗法
Immunotherapy. 2013 Dec;5(12):1267-9. doi: 10.2217/imt.13.131.
8
Current advancements and future perspectives of immunotherapy in colorectal cancer research.免疫疗法在结直肠癌研究中的当前进展和未来展望。
Eur J Pharmacol. 2021 Feb 15;893:173819. doi: 10.1016/j.ejphar.2020.173819. Epub 2020 Dec 29.
9
Immunotherapy in colorectal cancer.结直肠癌的免疫治疗
Clin Adv Hematol Oncol. 2018 Jan;16(1):22-24.
10
The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.免疫基因组学在结直肠癌中的临床意义：精准医学的途径。
Cancer. 2018 Apr 15;124(8):1650-1659. doi: 10.1002/cncr.31214. Epub 2018 Jan 9.
引用本文的文献
1
Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis.将程序性死亡1/程序性死亡配体1抑制剂添加到转移性结直肠癌的一线标准治疗方案中：一项荟萃分析。
World J Clin Oncol. 2025 Aug 24;16(8):106873. doi: 10.5306/wjco.v16.i8.106873.
2
Machine Learning-Derived Neddylation Gene Signature for Predicting Prognosis and Immunotherapy Benefits in Colorectal Cancer.用于预测结直肠癌预后和免疫治疗获益的机器学习衍生的Neddylation基因特征
Immunotargets Ther. 2025 Aug 25;14:931-952. doi: 10.2147/ITT.S532644. eCollection 2025.
3
Cancer-specific senescence signature promotes malignant phenotypes and immunotherapy resistance in colorectal cancer.癌症特异性衰老特征促进结直肠癌的恶性表型和免疫治疗抗性。
Front Immunol. 2025 Jul 24;16:1603787. doi: 10.3389/fimmu.2025.1603787. eCollection 2025.
4
Multi-Omics Analysis and Real-World Data Validation of Serine Metabolism-Related Genes in Colorectal Cancer.结直肠癌中丝氨酸代谢相关基因的多组学分析及真实世界数据验证
J Cell Mol Med. 2025 Jul;29(13):e70721. doi: 10.1111/jcmm.70721.
5
Folate metabolism-associated CYP26A1 is a clinico-immune target in colorectal cancer.叶酸代谢相关的细胞色素P450 26A1是结直肠癌的临床免疫靶点。
Genes Immun. 2025 Jul 3. doi: 10.1038/s41435-025-00342-6.
6
Recent advances and challenges in colorectal cancer: From molecular research to treatment.结直肠癌的最新进展与挑战：从分子研究到治疗
World J Gastroenterol. 2025 Jun 7;31(21):106964. doi: 10.3748/wjg.v31.i21.106964.
7
The Tumor-Associated Neutrophils-Related Signatures Predict Prognosis and Indicate Immune Landscape in Colorectal Carcinoma.肿瘤相关中性粒细胞相关特征预测结直肠癌预后并指示免疫格局
Mediators Inflamm. 2025 Jun 5;2025:7259278. doi: 10.1155/mi/7259278. eCollection 2025.
8
Long non-coding RNA TMEM51-AS1 inhibits colorectal cancer progression.长链非编码RNA TMEM51-AS1抑制结直肠癌进展。
Discov Oncol. 2025 May 23;16(1):878. doi: 10.1007/s12672-025-02676-z.
9
Identification of the "Collagen-Macrophage" sub-category of patients with colorectal cancer as an extension of the CMS4 subtype with THBS2 as a therapeutic target.将结直肠癌患者的“胶原蛋白-巨噬细胞”亚类鉴定为CMS4亚型的扩展，并将THBS2作为治疗靶点。
BMC Gastroenterol. 2025 May 8;25(1):342. doi: 10.1186/s12876-025-03918-8.
10
ATM is associated with the prognosis of colorectal cancer: a systematic review.共济失调毛细血管扩张症突变基因（ATM）与结直肠癌的预后相关：一项系统综述
Front Oncol. 2025 Mar 12;15:1470939. doi: 10.3389/fonc.2025.1470939. eCollection 2025.
本文引用的文献
1
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.一线纳武利尤单抗联合低剂量伊匹木单抗治疗微卫星高度不稳定/错配修复缺陷转移性结直肠癌：II期CheckMate 142研究
J Clin Oncol. 2022 Jan 10;40(2):161-170. doi: 10.1200/JCO.21.01015. Epub 2021 Oct 12.
Zotero 插件